TNFSF10 and neoplasm: Apo2L/TRAIL is a member of the TNF superfamily of cytokines and represents a most valuable candidate for cancer therapy because it initiates apoptosis preferably in tumor cells over normal cells, both in vitro and in vivo in nonhuman primates and mice [8–10].